Enzo Biochem/GeneNews ink colorectal cancer test pact
This article was originally published in The Gray Sheet
Executive Summary
Enzo gains rights to market GeneNews' ColonSentry colorectal cancer test in New York and New Jersey under an agreement announced Nov. 18. The firm said it hopes to launch the test in the second half of 2010 after securing CLIA certification and third-party reimbursement. According to GeneNews, ColonSentry is the first blood test for colorectal cancer, and offers a non-invasive method of assessing cancer risk that may improve screening compliance rates and lead to earlier detection
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.